Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 536 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo gel Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

NCT03945643
View directory record Official record
Conditions
Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 14, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717
View directory record Official record
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 14, 2026, 4:14 PM EDT
Not listed Not applicable Interventional

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

NCT02402374
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Autologous platelet rich plasma gel, Placebo
Device
Lead sponsor
Regen Lab SA
Industry
Eligibility
18 Years to 95 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Starting a Testosterone and Exercise Program After Hip Injury

NCT02938923
View directory record Official record
Conditions
Hip Fracture, Frailty, Sarcopenia
Interventions
Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

NCT01989663
View directory record Official record
Conditions
HIV
Interventions
1% vaginally applied tenofovir gel, Tenofovir film- 10mg, Tenofovir Film-40 mg, HEC Placebo Gel, Placebo Vaginal Film
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 14, 2026, 4:14 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

NCT00074425
View directory record Official record
Conditions
HIV Infections
Interventions
BufferGel, PRO 2000/5 Gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT03429140
View directory record Official record
Conditions
Anterior Cruciate Ligament
Interventions
Gel-One, Saline Placebo
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 33 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

NCT03301870
View directory record Official record
Conditions
Irritation Potential of Topic Agent
Interventions
ATx201 Gel 2%, ATx201 Gel 4%, Positive Control, Negative Control, ATx201 Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain

NCT03566979
View directory record Official record
Conditions
Post-operative Dental Pain
Interventions
Test naproxen sodium tablet, Commercial naproxen sodium tablet, Commercial naproxen sodium liquid gels capsule, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00916006
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Testosterone, Goserelin acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 75 Years · Male only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 14, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

NCT02606994
View directory record Official record
Conditions
Mucositis, Neoplasms
Interventions
Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
Drug
Lead sponsor
Oral Defense, LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

NCT02169154
View directory record Official record
Conditions
Pain
Interventions
1% Diclofenac Sodium, 3% Menthol, 0.09% Menthol, 0.2% Sodium Lauryl Sulfate, 0.9% Saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

NCT02709005
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
5% Monolaurin Vaginal Gel, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

NCT02596451
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac Sodium gel, 1%, Voltaren® Gel, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
35 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
44
States / cities
Mesa, Arizona • Anaheim, California • Canoga Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Astaxanthin on Cognition in Recreationally Active Females

NCT06460181
View directory record Official record
Conditions
Mental Fatigue
Interventions
Astaxanthin, Placebo
Dietary Supplement
Lead sponsor
University of North Alabama
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Florence, Alabama
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 14, 2026, 4:14 PM EDT